Mayo Clinic researchers identified a potential new approach to treating glioblastoma to improve the effectiveness of existing chemotherapy.
News|Articles|September 10, 2026
Systemic Therapy for Advanced Cutaneous Squamous Cell Carcinoma Evidence and Clinical Decision-Making
Listen
0:00 / 0:00
Advertisement
KEY TAKEAWAYS
- The introduction of immune checkpoint inhibitors for advanced cutaneous squamous cell carcinoma (cSCC) in 2018 fundamentally changed treatment expectations from managing symptoms to achieving potential cures with durable responses.
- Treatment for cSCC evolved from having only modest chemotherapy options to now having three different checkpoint inhibitors, allowing for individualized treatment selection based on patient factors.
- Modern immunotherapy approaches for cSCC offer better tolerability profiles compared to traditional chemotherapy combinations, with newer agents showing particularly low toxicity rates.
- Current and future directions emphasize personalized medicine through biomarker development, combination strategies, and determining optimal treatment timing and duration for each patient with cSCC.
Advertisement
Related to this article
In the phase 2 RESTORE-PV trial, DISC-3405 cut phlebotomy events and maintained hematocrit below 45% in patients with polycythemia vera.
Gabriela Hobbs, MD, explains the importance of risk assessment and using disease factors to drive management approaches in myelofibrosis.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss HER2-mutant NSCLC testing, treatment selection, and sequencing strategies.
OS in the LIVERATION trial of namodenoson in advanced HCC appeared longer than anticipated, prompting consideration of an earlier interim analysis.
Micvotabart pelidotin produced a 36% confirmed ORR and a 6.2-month median PFS in pretreated recurrent/metastatic head and neck squamous cell carcinoma.
Patients with advanced abdominal cancers who are not candidates for tumor-removing surgery now have access to a treatment that may help control disease within the abdomen, reduce symptoms, preserve quality of life, and potentially extend survival.
The FDA approved sevabertinib for advanced or metastatic nonsquamous NSCLC harboring HER2 (ERBB2) TKD activating mutations.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Sevabertinib for Advanced HER2 TKD–Mutated Nonsquamous NSCLC
2
TKD Mutation Status and CNS Data Guide Frontline Sequencing in HER2-Mutant NSCLC
3
Micvotabart Pelidotin Monotherapy Yields Responses in Pretreated Recurrent/Metastatic HNSCC
4
Durvalumab Plus Tarlatamab Boosts Survival as First-Line ES-SCLC Maintenance
5